ORMPHIGH SIGNALFINANCIAL10-K

ORMP achieved a dramatic turnaround from a $19.1M net loss to $64.0M net income while substantially reducing debt by 99.7% and planning new clinical trials for oral insulin.

This represents a fundamental transformation of the company's financial profile, with the shift to profitability likely driven by non-operating gains or asset sales given the modest revenue increase. The massive debt reduction suggests either a major refinancing, debt conversion, or settlement that has strengthened the balance sheet considerably.

Comparing 2026-03-26 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

ORMP experienced a remarkable financial transformation with net income swinging from -$19.1M to +$64.0M, total debt plummeting 99.7% from $9.7M to just $25K, and total assets growing 48.7% to $230.9M. Current liabilities increased significantly by 235.7%, but this was more than offset by the dramatic improvement in profitability and debt reduction. The overall picture signals a major restructuring or capital event that has fundamentally improved the company's financial position, though investors should scrutinize the sources of the profit surge given relatively modest operational revenue growth of 49.3%.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+435.3%
-$19.1M→$64.0M

Net income grew 435.3% — bottom-line growth signals improving overall business health.

Current Liabilities
Balance Sheet
+235.7%
$5.7M→$19.1M

Current liabilities surged 235.7% — significant near-term obligations; verify ability to meet short-term debt.

Total Debt
Balance Sheet
-99.7%
$9.7M→$25K

Debt reduced 99.7% — deleveraging strengthens balance sheet and reduces financial risk.

Share Buybacks
Cash Flow
+90.9%
$2.5M→$4.7M

Share repurchases increased 90.9% — management returning capital, signals confidence in intrinsic value.

Accounts Receivable
Balance Sheet
-83.8%
$543K→$88K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Capital Expenditure
Cash Flow
-50%
$18K→$9K

Capex reduced 50% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Revenue
P&L
+49.3%
$1.3M→$2.0M

Strong top-line growth of 49.3% — accelerating demand or successful expansion into new markets.

Total Assets
Balance Sheet
+48.7%
$155.3M→$230.9M

Asset base grew 48.7% — expansion through organic growth, acquisitions, or capital deployment.

Total Deposits
Balance Sheet
-37.7%
-$8.0M→-$11.0M

Deposits declined 37.7% — significant outflows warrant immediate investigation into funding stability.

Stockholders Equity
Balance Sheet
+36.6%
$146.3M→$199.7M

Equity base grew 36.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-27
ADDED
As of March 26, 2026, the registrant had 40,446,179 shares of common stock issued and outstanding.
In addition, we allocate capital to strategic investments in healthcare and life sciences companies that we believe complement our long-term business objectives and technology focus.
We have developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins.
We intend to initiate, in the second half of 2026, a 60-patient, US-based clinical trial designed to validate the robustness of our oral insulin formulation in defined patient population.
The trial is designed to use the smallest adequately powered patient population expected to obtain such validation in what we believe to be the shortest time possible, providing a cost-effective approach to generate additional compelling evidence and refine our patient selection criteria for future potential regulatory submissions.
+7 more — sign up free →
REMOVED
As of March 27, 2025, the registrant had 40,850,455 shares of common stock issued and outstanding.
We have developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins.
On January 11, 2023, we announced that the Phase 3 oral insulin trial (ORA-D-013-1) did not meet its primary or secondary endpoints.
As a result, we terminated this trial and a parallel Phase 3, ORA-D-013-2 clinical trial.
In 2023, we completed an analysis of the ORA-D-013-1 Phase 3 trial data and found that subpopulations of patients with pooled specific parameters, such as body mass index, or BMI, baseline HbA1c and age, responded well to oral insulin.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →